Charles Schwab Investment Management Inc. Invests $156,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

Charles Schwab Investment Management Inc. bought a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,977 shares of the company’s stock, valued at approximately $156,000.

Several other large investors have also recently bought and sold shares of DCTH. Polar Asset Management Partners Inc. acquired a new position in shares of Delcath Systems during the 3rd quarter worth about $1,594,000. Principal Financial Group Inc. acquired a new stake in shares of Delcath Systems during the 3rd quarter worth about $808,000. Virtu Financial LLC purchased a new stake in Delcath Systems during the third quarter worth approximately $289,000. Baader Bank Aktiengesellschaft acquired a new position in Delcath Systems in the fourth quarter valued at approximately $204,000. Finally, Private Advisor Group LLC purchased a new position in Delcath Systems in the fourth quarter valued at approximately $153,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Down 1.3 %

Shares of NASDAQ DCTH opened at $12.57 on Wednesday. The stock has a market cap of $419.88 million, a P/E ratio of -9.31 and a beta of 0.82. Delcath Systems, Inc. has a twelve month low of $4.26 and a twelve month high of $16.97. The stock has a 50 day moving average of $14.51 and a two-hundred day moving average of $12.09.

Delcath Systems (NASDAQ:DCTH) last announced its earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The business had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same period in the previous year, the firm earned ($0.48) earnings per share. As a group, research analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. Craig Hallum boosted their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.